Axcelis Technologies Inc ACLS is slated to report first-quarter 2023 results on May 3. The Zacks Consensus Estimate for first-quarter revenues is pegged at $240 million, which suggests growth of ...

Routine drugs are not recommended for ACLS, said Berg. Epinephrine at a fixed dose can be used early, but it is most beneficial in patients with unshockable rhythms, he said. The guidelines ...

Axcelis Technologies, Inc. (NASDAQ:ACLS) engages in the design, manufacturing, and servicing of ion implantation and other processing equipment used in the fabrication of semiconductor chips.

Fintel reports that on April 21, 2025, B. Riley Securities downgraded their outlook for Axcelis Technologies (NasdaqGS:ACLS) from Buy to Neutral. Analyst Price Forecast Suggests 110.73% Upside As ...

Below is Validea's guru fundamental report for AXCELIS TECHNOLOGIES INC (ACLS). Of the 22 guru strategies we follow, ACLS rates highest using our Twin Momentum Investor model based on the ...

Axcelis Technologies Inc (Symbol: ACLS) saw options trading volume of 5,083 contracts, representing approximately 508,300 underlying shares or approximately 66.9% of ACLS's average daily trading ...